PureTech Awarded up to $11.4 Million from U.S. Department of Defense to Advance LYT-300 (Oral Allopregnanolone) for Fragile X-associated Tremor/Ataxia Syndrome

Planning underway for Phase 2 trial of LYT-300 in Fragile X-associated Tremor/Ataxia Syndrome


LYT-300 is also being evaluated in a Phase 2a trial for anxiety disorders, and a Phase 2a in patients...

Related Keywords

California ,United States ,Christopher Porter ,Eric Elenko ,Randi Hagerman ,Angewandte Chemie ,Us Army Medical Research Acquisition Activity ,Drug Administration ,Development Directorate ,Department Of Defense ,Puretech Health ,Porter Research Group ,Office Of The ,University Of California ,Health Affairs ,Us Department Of Defense Do ,Us Army Medical Research ,Peer Reviewed Medical Research Program ,Twitter ,Defense Health Agency ,Fragilex Research ,Nasdaq ,Fragilex Associated Tremor Ataxia Syndrome ,Fragilex Messenger Ribonucleoprotein Gene ,Medical Director ,Behavioral Dyscontrol Scale ,Chief Innovation Officer ,Wholly Owned Programs ,Assistant Secretary ,Medical Research Acquisition Activity ,Medical Research ,Development Command ,Ataxia Syndrome ,Fragilex Spectrum Disorders ,Fragilex Associated ,Monash Institute ,Pharmaceutical Sciences ,Nature Metabolism ,Controlled Release ,Founded Entities ,Private Securities Litigation Reform Act ,Annual Report ,Open Label Allopregnanolone Treatment ,Genetic Engineering ,Markets ,